Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2)

Benjamin W Van Tassell, Leo F Buckley, Salvatore Carbone, Cory R Trankle, Justin M Canada, Dave L Dixon, Nayef Abouzaki, Claudia Oddi-Erdle, Giuseppe Biondi-Zoccai, Ross Arena, Antonio Abbate, Benjamin W Van Tassell, Leo F Buckley, Salvatore Carbone, Cory R Trankle, Justin M Canada, Dave L Dixon, Nayef Abouzaki, Claudia Oddi-Erdle, Giuseppe Biondi-Zoccai, Ross Arena, Antonio Abbate

Abstract

Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of confirmed HF cases in the United States. However, there are no highly effective evidence-based treatments currently available for these patients. Inflammation correlates positively with adverse outcomes in HF patients. Interleukin (IL)-1, a prototypical inflammatory cytokine, has been implicated as a driver of diastolic dysfunction in preclinical animal models and a pilot clinical trial. The Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) is a phase 2, 2:1 randomized, double-blind, placebo-controlled clinical trial that will test the hypothesis that IL-1 blockade with anakinra (recombinant human IL-1 receptor antagonist) improves (1) cardiorespiratory fitness, (2) objective evidence of diastolic dysfunction, and (3) elevated inflammation in patients with HFpEF (http://www.ClinicalTrials.gov NCT02173548). The co-primary endpoints will be placebo-corrected interval changes in peak oxygen consumption and ventilatory efficiency at week 12. In addition, secondary and exploratory analyses will investigate the effects of IL-1 blockade on cardiac structure and function, systemic inflammation, endothelial function, quality of life, body composition, nutritional status, and clinical outcomes. The D-HART2 clinical trial will add to the growing body of evidence on the role of inflammation in cardiovascular disease, specifically focusing on patients with HFpEF.

Keywords: Heart Failure; Interleukin-1; clinical trial study design.

Conflict of interest statement

The authors declare no potential conflicts of interest.

© 2017 Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Effects of IL‐1 blockade on cardiorespiratory fitness in a pilot clinical trial. A randomized, double‐blind, crossover, pilot study evaluated the effects of IL‐1 blockade in patients with HFpEF. Abbreviations: HFpEF, heart failure with preserved ejection fraction; IL‐1, interleukin 1; peak VO2, peak oxygen consumption; VE/VCO2, minute ventilation–carbon dioxide production relationship
Figure 2
Figure 2
Design of the Diastolic Heart Failure–Anakinra Response Trial 2 (D‐HART2). Abbreviations: CPET, cardiopulmonary exercise testing; echo, echocardiography; HFpEF, heart failure with preserved ejection fraction

References

    1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259.
    1. Van Tassell BW, Toldo S, Mezzaroma E, et al. Targeting interleukin‐1 in heart disease. Circulation. 2013;128:1910–1923.
    1. Dinarello CA. Interleukin‐1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720–3732.
    1. Kumar A, Thota V, Dee L, et al. Tumor necrosis factor α and interleukin 1‐β are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183:949–958.
    1. Van Tassell BW, Raleigh JMV, Abbate A. Targeting interleukin‐1 in heart failure and inflammatory heart disease. Curr Heart Fail Rep. 2015;12:33–41.
    1. Van Tassell BW, Seropian IM, Toldo S, et al. Interleukin‐1β induces a reversible cardiomyopathy in the mouse. Inflamm Res. 2013;62:637–640.
    1. Toldo S, Mezzaroma E, Bressi E, et al. Interleukin‐1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J Cardiovasc Pharmacol. 2014;64:1–6.
    1. Chow SL, O'Barr SA, Peng J, et al. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure. J Card Fail. 2011;17:181–187.
    1. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055–2059.
    1. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491.
    1. Shah SJ, Marcus GM, Gerber IL, et al. High‐sensitivity C‐reactive protein and parameters of left ventricular dysfunction. J Card Fail. 2006;12:61–65.
    1. Canada JM, Fronk DT, Cei LF, et al. Usefulness of C‐reactive protein plasma levels to predict exercise intolerance in patients with chronic systolic heart failure. Am J Cardiol. 2015;117:116–120.
    1. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254–1268.
    1. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95:9C–16C.
    1. Van Tassell BW, Arena R, Biondi‐Zoccai G, et al. Effects of interleukin‐1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D‐HART Pilot Study). Am J Cardiol. 2014;113:321–327.
    1. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–2550.
    1. Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1892.
    1. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiograph. J Am Soc Echocardiogr. 2005;18:1440–1463.
    1. AbouEzzeddine OF, Haines P, Stevens S, et al. Galectin‐3 in heart failure with preserved ejection fraction A RELAX trial substudy. JACC Heart Fail. 2015;3:245–252.
    1. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol . 2002;40:1531–1540.
    1. Balady GJ, Arena R, Sietsema K, et al. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122:191–225.
    1. Arena R, Humphrey R, Peberdy MA, et al. Predicting peak oxygen consumption during a conservative ramping protocol: implications for the heart failure population. J Cardiopulm Rehabil. 2003;23:183–189.
    1. Rector T. Minnesota Living with Heart Failure Questionnaire. . Accessed December 11, 2015.
    1. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self‐administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64:651–654.
    1. Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442–451.
    1. Bensimhon DR, Leifer ES, Ellis SJ, et al; HF‐ACTION Trial Investigators. Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training). Am J Cardiol . 2008;102:712–717.
    1. Redfield MM, Chen HH, Borlaug BA, et al; RELAX Trial. Effect of phosphodiesterase‐5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA . 2013;309:1268–1277.
    1. Edelmann F, Wachter R, Schmidt AG, et al; Aldo‐DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo‐DHF randomized controlled trial. JAMA. 2013;309:781–791.
    1. Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315:36–46.
    1. Cahalin LP, Chase P, Arena R, et al. A meta‐analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart Fail Rev. 2013;18:79–94.
    1. Arena R, Myers J, Aslam SS, et al. Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J. 2004;147:354–360.
    1. Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all‐cause mortality and cardiovascular events in healthy men and women. JAMA. 2009;301:2024–2035.
    1. Barron A, Dhutia N, Mayet J, et al. Test‐retest repeatability of cardiopulmonary exercise test variables in patients with cardiac or respiratory disease. Eur J Prev Cardiol. 2014;21:445–453.
    1. Scott JM, Haykowsky MJ, Eggebeen J, et al. Reliability of peak exercise testing in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2012;110:1809–1813.
    1. Skinner JS, Wilmore KM, Jaskolska A, et al. Reproducibility of maximal exercise test data in the HERITAGE family study. Med Sci Sports Exerc. 1999;31:1623–1628.
    1. Russell SD, McNeer FR, Beere PA, et al. Improvement in the mechanical efficiency of walking: an explanation for the “placebo effect” seen during repeated exercise testing of patients with heart failure. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. Am Heart J . 1998;135:107–114.
    1. Van Laethem C, De Sutter J, Peersman W, et al. Intratest reliability and test‐retest reproducibility of the oxygen uptake efficiency slope in healthy participants. Eur J Cardiovasc Prev Rehabil. 2009;16:493–498.
    1. Wang M, Yip GW, Wang AY, et al. Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol. 2003;41:820–826.
    1. Borlaug BA, Kass DA. Ventricular‐vascular interaction in heart failure. Heart Fail Clin. 2008;4:23–36.
    1. Carbone S, Lavie CJ, Arena RA. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc. 2017;92:266–279.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner